

S1701



A Randomized Phase II trial of Carboplatin-Paclitaxel with or without Ramucirumab in Patients with Unresectable Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma

A Thymic Cancer Trial
Supported By
the Lung Cancer Committee

Potential Study Participants

- Locally advanced or metastatic unresectable thymic carcinoma with no prior systemic therapy
- Recurrent unresectable thymic carcinoma may have had prior neoadjuvant or adjuvant chemotherapy as described in the protocol
- Thymic carcinoma may also be defined as “thymic epithelial malignancy, consistent with thymic carcinoma”, or “WHO Type C thymic epithelial tumor”, or “thymic epithelial malignancy” with radiographic imaging consistent with thymic carcinoma


Randomized Phase II Trial
studying a new triplet
combination for Thymic
Carcinoma, a rare malignancy

Recently amended eligible
diagnostic cancer types

We need your participation
to reach the accrual goal of
66 patients

* Please refer to the protocol for full eligibility criteria.

Study Schema



Study Chairs

Anne Tsao, MD
M.D. Anderson Cancer Center

Marianna Koczywas, MD
City of Hope National Medical Center

For more information, please visit:
<https://www.swog.org/clinical-trials/s1701>